Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Volume 47, Issue 8
Displaying 1-9 of 9 articles from this issue
Regular Article
  • Xiaohua Hou, Jiangbin Wang, Qin Du, Dean Tian, Naizhong Hu, Deliang Li ...
    2024 Volume 47 Issue 8 Pages 1405-1414
    Published: August 01, 2024
    Released on J-STAGE: August 01, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material
    Editor's pick

    This pooled analysis of two phase 3 studies investigates efficacy and safety of vonoprazan-based quadruple therapy for Helicobacter pylori (H. pylori) eradication in Asian patients with peptic ulcers. The researchers compared vonoprazan based regimens to the lansoprazole-based quadruple therapy. The results demonstrate that vonoprazan-based therapy was effective and safe for eradicating H. pylori. The eradication rates achieved with vonoprazan-based quadruple therapy were noninferior to those achieved with lansoprazole-based quadruple therapy and exceeded clinically relevant threshold (90%) for efficacy. This finding suggests that vonoprazan-based quadruple therapy may be a valuable new treatment option for H. pylori infection in patients with peptic ulcers.

  • Yuji Maruo, Masahiro Shiraishi, Mitsue Hibino, Jiro Abe, Atsuhito Take ...
    2024 Volume 47 Issue 8 Pages 1415-1421
    Published: August 06, 2024
    Released on J-STAGE: August 06, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material
    Editor's pick

    [Highlighted Paper selected by Editor-in-Chief]
    The authors previously developed a drug delivery system targeting mitochondria (MITO-Porter) by using a microfluidic device to encapsulate Coenzyme Q10 (CoQ10) on a large scale. Herein, the authors successfully activated mitochondrial functions in mesenchymal stem cells (MSCs) using this unique technique by controlling the amount of CoQ10 encapsulated in MITO-Porter. While the efficacy of MSC transplantation therapy has been reported for various diseases, it is still in the developmental stage. This mitochondrial-activated MSCs offers a promising tool to improve their transplantation therapy, with the potential to accelerate the clinical application of MSCs.

  • Ryosuke Negoro, Ayu Ouchi, Sayaka Deguchi, Kazuo Takayama, Takuya Fuji ...
    2024 Volume 47 Issue 8 Pages 1422-1428
    Published: August 08, 2024
    Released on J-STAGE: August 08, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material
    Editor's pick

    This groundbreaking study introduces a refined hepatocyte model that accurately replicates the impact of CYP2D6*10, a prevalent mutation in East Asian populations. Using the PITCh genome editing system, researchers successfully engineered HepG2 cells to express six key drug-metabolizing enzymes, including the CYP2D6*10 variant. The resulting CYP2D6*10 KI-HepG2 cells exhibited reduced CYP2D6 protein expression and metabolic activity, mirroring the mutation's effects in vivo. This novel model promises to enhance drug metabolism predictions and hepatotoxicity studies, particularly for East Asian populations, potentially revolutionizing drug development and safety assessments.

  • Yusuke Iguchi, Yukiko Yamashita, Keigo Gohda, Keisuke Oda, Ko Fujimori ...
    2024 Volume 47 Issue 8 Pages 1429-1436
    Published: August 13, 2024
    Released on J-STAGE: August 13, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material
  • Yanqin Song, Jian Ruan, Shuxian Liu, Haizhou Yu
    2024 Volume 47 Issue 8 Pages 1437-1446
    Published: August 15, 2024
    Released on J-STAGE: August 15, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Editor's pick

    Prostate cancer is a common malignant tumor of the urinary tract in men. It is the fifth leading cause of cancer death in men worldwide and the second most common malignancy. The results of this study provide an effective way to improve the anti-cancer effect of docetaxel. Bisdemethoxycurcumin can be used as an anticancer adjuvant in combination chemotherapy. These authors suggest that the combination of bisdemethoxycurcumin and docetaxel may be more effective in treating prostate cancer than docetaxel alone. However, the development of bisdemethoxycurcumin as a sensitizer requires more detailed studies to evaluate the feasibility and benefits of its clinical use.

  • Koyo Nakamura, Kazuaki Matsumoto, Yuki Enoki, Kazuaki Taguchi, Shuji Y ...
    2024 Volume 47 Issue 8 Pages 1447-1451
    Published: August 21, 2024
    Released on J-STAGE: August 21, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
Note
  • Tomoya Abe, Atsunobu Sagara, Takayuki Suzuki, Daichi Okada, Kazumasa M ...
    2024 Volume 47 Issue 8 Pages 1452-1455
    Published: August 21, 2024
    Released on J-STAGE: August 21, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
  • Masashi Imai, Keiichi Hiramoto, Shota Tanaka, Kazuya Ooi
    2024 Volume 47 Issue 8 Pages 1456-1459
    Published: August 28, 2024
    Released on J-STAGE: August 28, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Editor's pick

    The authors investigated sex differences in weight gain induced by the anticancer drug 5-fluorouracil (5-FU) in mice. The results revealed a decrease in estradiol and an increase in ghrelin in female mice, along with elevated noradrenaline levels. The increase in noradrenaline inhibits the estradiol-producing enzyme aromatase and raises adrenergic receptors in the ovaries. This suggests that 5-FU treatment promotes weight gain in female mice by lowering estradiol levels and increasing ghrelin levels through sympathetic nerve stimulation, which enhances appetite. This study aims to elucidate the mechanism of 5-FU-induced weight gain in women with breast cancer, as reported in clinical practice.

Regular Article
  • Haruka Sagawa, Hayato Kizaki, Kodai Yoshikawa, Tadamasa Kamimura, Shin ...
    2024 Volume 47 Issue 8 Pages 1460-1466
    Published: August 28, 2024
    Released on J-STAGE: August 28, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material
feedback
Top